EUVIMEDEUVIMED entdecken
Multizentrische StudieVergleichsstudieOpen Access · CC BY-NC-ND 4.0

Real‐World Effectiveness and Safety of Pembrolizumab–Lenvatinib Versus Axitinib‐Based Regimens in Metastatic Clear Cell Renal Cell Carcinoma: A Multicenter Retrospective Study

Kohei Kobatake iD, Keisuke Goto, Akira Fujita, Takashi Babasaki, Takeshi Ueno, Yoshimasa Kurimura, Kenichiro Fukuoka iD, Fumiaki Kirishima iD, Kensuke Nishida, Tetsutaro Hayashi, Nobuyuki Hinata iD

International Journal of Urology · 2026-04 · 33 (4)

DOI: 10.1111/iju.70461 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift International Journal of Urology, online erschienen am 14.04.2026. Verfasst von Kohei Kobatake und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Antibodies, Monoclonal, Humanized, Axitinib, Kidney Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To compare the real‐world effectiveness and safety of pembrolizumab plus lenvatinib with axitinib‐based regimens (avelumab plus axitinib or pembrolizumab plus axitinib) as first‐line therapy for metastatic clear cell renal cell carcinoma.

Methods

We retrospectively analyzed 107 patients treated with immuno‐oncology plus vascular endothelial growth factor inhibitor combinations between 2017 and 2025. Propensity score matching (1:1, 0.2 caliper) generated 42 matched pairs. Objective response rate, progression‐free survival, overall survival, and adverse events were assessed. Multivariable logistic regression and Cox regression analyses were performed in the overall cohort, and conditional logistic regression and stratified Cox regression analyses were applied in the matched cohort.

Results

In the matched cohort, pembrolizumab plus lenvatinib demonstrated a significantly higher objective response rate than axitinib‐based regimens. The incidence of any‐grade and grade ≥ 3 adverse events was similar between regimens. However, pembrolizumab plus lenvatinib was associated with higher rates of hypertension (including grade ≥ 3 hypertension), fatigue, appetite loss, and rash in the full‐dose subgroup. Progression‐free and overall survival did not differ significantly. Multivariate analyses identified pembrolizumab plus lenvatinib treatment as an independent predictor of objective response, whereas survival outcomes were associated with clinical factors rather than the regimen type.

Conclusions

Pembrolizumab plus lenvatinib achieved a superior tumor response to axitinib‐based regimens, whereas survival outcomes were comparable. Treatment selection should balance enhanced antitumor activity with differences in toxicity profiles.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellAntibodies, Monoclonal, HumanizedAxitinibKidney NeoplasmsQuinolinesPhenylurea CompoundsAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleRetrospective StudiesMaleMiddle AgedAgedProgression-Free SurvivalTreatment Outcome

Stichwörter der Autor:innen

clear cell renal cell carcinomalenvatinibmetastatic renal cell carcinomapembrolizumabreal‐world evidence

Substanzen

Antibodies, Monoclonal, HumanizedAxitinibpembrolizumablenvatinibQuinolinesPhenylurea Compounds

Autor:innen und Institutionen

  • Department of Urology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
  • Department of Urology, NHO Fukuyama Medical Center, Fukuyama, Japan.
  • Department of Urology, Hiroshima City Asa Citizens Hospital, Hiroshima, Japan.
  • Department of Urology, JA Hiroshima General Hospital, Hatsukaichi, Japan.
  • Department of Urology, Hiroshima Prefectural Hospital, Hiroshima, Japan.
  • Department of Urology, NHO Kure Medical Center, Kure, Japan.

ORCID-Profile: Kohei Kobatake, Kenichiro Fukuoka, Fumiaki Kirishima, Nobuyuki Hinata

Zitieren

APA

Kobatake, K., Goto, K., Fujita, A., Babasaki, T., Ueno, T., Kurimura, Y., Fukuoka, K., Kirishima, F., Nishida, K., Hayashi, T., & Hinata, N. (2026). Real‐World Effectiveness and Safety of Pembrolizumab–Lenvatinib Versus Axitinib‐Based Regimens in Metastatic Clear Cell Renal Cell Carcinoma: A Multicenter Retrospective Study. International Journal of Urology, 33(4). https://doi.org/10.1111/iju.70461

Vancouver

Kobatake K, Goto K, Fujita A, Babasaki T, Ueno T, Kurimura Y, et al. Real‐World Effectiveness and Safety of Pembrolizumab–Lenvatinib Versus Axitinib‐Based Regimens in Metastatic Clear Cell Renal Cell Carcinoma: A Multicenter Retrospective Study. International Journal of Urology. 2026;33(4). doi:10.1111/iju.70461

BibTeX
@article{Kobatake2026,
  author = {Kobatake, Kohei and Goto, Keisuke and Fujita, Akira and Babasaki, Takashi and Ueno, Takeshi and Kurimura, Yoshimasa and Fukuoka, Kenichiro and Kirishima, Fumiaki and Nishida, Kensuke and Hayashi, Tetsutaro and Hinata, Nobuyuki},
  title = {Real‐World Effectiveness and Safety of Pembrolizumab–Lenvatinib Versus Axitinib‐Based Regimens in Metastatic Clear Cell Renal Cell Carcinoma: A Multicenter Retrospective Study},
  journal = {International Journal of Urology},
  year = {2026},
  volume = {33},
  number = {4},
  doi = {10.1111/iju.70461}
}
Kostenlos starten →